+254 730 162 110 /
+ 254 730 162 000


Congratulations Prof. George Warimwe

Congratulations to George Warimwe for being conferred the title full Professor of Vaccinology at the University of Oxford. “I’m truly honoured by this recognition. It is testimony to the excellent mentorship received over the years and the immense contribution to vaccine R&D in Africa by the team of amazingly talented scientists that work with me […]
Read More

Community and Public Engagement at the KEMRI Wellcome Research Programme

Read more about our Community and Public Engagement Strategy here: https://kemri-wellcome.org/wp-content/uploads/2022/07/Community-and-Publication-Engagement-brief.pdf
Read More

Policy Brief – Projections of COVID-19 Cases and Deaths Following Schools Reopening

Summary We applied models that predicted the pattern of the first peak of COVID-19 cases in late July 2020 but did not predict the second peak in November 2020. The peak in November 2020 can be explained by now adding to the model: a) data that has become available on negative test numbers; b) an […]
Read More

Receiving and Responding to Community Feedback During Health System Crises: Lessons from Early days of the COVID-19 Pandemic Response in Kilifi County

Health system responsiveness, defined as how the health system reacts to input from the public or citizens is one of the goals of the health system alongside fairness in financing and health service outcomes. Listening to and responding to public inputs and feedback can lead to a health system that is stronger and fairer to […]
Read More

Prevalence of vitamin D deficiency in Africa: a systematic review and meta-analysis

Vitamin D deficiency is an important public problem worldwide because of its link to many diseases and poor health outcomes. However, there is limited data on the vitamin D status of African populations. We aimed to determine the prevalence and risk factors associated with vitamin D deficiency in Africa. To achieve this, we searched for, […]
Read More

Knowledge brokering platform launched to support health systems in the African region

[PRESS RELEASE] Brazzaville, 23 November 2020 – The World Health Organization (WHO) and partners launched an online platform today to promote the exchange of evidence and experience across countries in the African region. By working to foster evidence-informed decision-making in an endeavor to re-engineer health service delivery, the initiative is expected to drive countries’ health […]
Read More

[Press Release] ChAdOx1 nCoV-19 trials in Kenya

Kenya has joined the global efforts in search of an effective vaccine for COVID-19 with the start of a trial evaluating a leading COVID-19 vaccine candidate ChAdOx1 nCoV-19. The trial team has vaccinated its first volunteers after receiving the necessary regulatory and ethical approvals, as well as the national ministry of health, and Kilifi county […]
Read More

‘Gender is not even a side issue…it’s a non-issue’: career trajectories and experiences from the perspective of male and female healthcare managers in Kenya.

Despite increased efforts at global, regional, and country level to promote gender equality, women continue to be under-represented in leadership positions across a range of sectors and geographic regions. In the health sector specifically, women comprise a substantial proportion of the global health workforce. However, women are over-represented in lower-paying, lower-status occupations and their representation […]
Read More

Majaribio ya chanjo ya ChAdOx1 nCoV-19: Maswali yanayoulizwa mara kwa mara

1. Je majaribio ya chanjo ya ChAdOx1 nCOV-19 ni nini? Majaribio haya yanalenga kutathmini ikiwa chanjo ya ChAdOx1 nCOV-19 ni salama, inafanya kazi na inapeana kinga dhidi ya COVID-19 kwa watu wazima wenye umri wa miaka 18 na zaidi 2. Majaribio ya chanjo hii yatachukuwa muda gani? Baada ya kuanza, majaribio yatafanyika kwa muda wa miezi 24. […]
Read More

ChAdOx1 nCOV-19 Vaccine Trial – Frequently Asked Questions about the Trial

1. What is the ChAdOx1 Vaccine Trial? This trial aims to assess whether the ChAdOx1 vaccine is safe, effective and provides immunity against COVID-19 in adults aged 18 years and above. 2. How long will the vaccine trial run? After starting, the trial will run for 24 months. 3. Why conduct the trial in Kenya? A vaccine which […]
Read More